An Update on the Pathways and Aspects of Epilepsy Treatment Targets

Ruksar      Sande; Pravin      Kale; Angel      Godad; Gaurav      Doshi
doi:10.2174/0115743624252836230924075249
Abstract

Epilepsy is a neurological disorder characterized by spontaneously occurring seizures known for several decades. Despite the availability of current anti-epileptic drugs, including Phenytoin, Valproate, Carbamazepine, Lamotrigine, Gabapentin, Vigabatrin, etc., a considerable 30 % of the epileptic population are drug-resistant to the available conventional medications. This suggests a need to find new drug therapy for the management of epilepsy. Moreover, prolonged use of a single drug or monotherapy can also lead to therapeutic failure owing to the inability of a single drug to exert the desired anti-epileptic effect. Hence, on the basis of the knowledge and understanding regarding the existing targets, novel agents having the ability to show therapeutic effects should be studied and investigated further. This article emphasizes the need to investigate and repurpose drug molecules for the management of epilepsy. The review elaborates on the potential targets, including Glutamate, EAAT (Excitatory nucleotide) Channel and mTOR (Mammalian Target of Rapamycin) pathway. Moreover, the discussion on the EAAT (Excitatory Amino Acid Transporters), RAS (Renin Angiotensin System), NHE (Na+/H+ exchangers), HCN (Hyperpolarization-activated cyclic nucleotide) targets and treatment approach has been supported by literature that sheds light on evidence which is validated via suitable preclinical and clinical studies.
Keywords: Epilepsy, excitatory amino acid transporters, glutamate, renin angiotensin system, hyperpolarization activated cyclic nucleotide channel, mammalian target of rapamycin.
Graphical Abstract

[1]
Steriade C, French J, Devinsky O. Epilepsy: Key experimental therapeutics in early clinical development. Expert Opin Investig Drugs  2020; 29(4): 373-83.
 [http://dx.doi.org/10.1080/13543784.2020.1743678] [PMID: 32172604]

[2]
Scharfman HE. Epilepsy.Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders.  2014; pp. 263-1.

[3]
Scharfman HE. The neurobiology of epilepsy. Curr Neurol Neurosci Rep  2007; 7(4): 348-54.
 [http://dx.doi.org/10.1007/s11910-007-0053-z] [PMID: 17618543]

[4]
Boison D, Rho JM. Epigenetics and epilepsy prevention: The therapeutic potential of adenosine and metabolic therapies. Neuropharmacology  2020; 167: 107741.
 [http://dx.doi.org/10.1016/j.neuropharm.2019.107741] [PMID: 31419398]

[5]
 Epilepsy-an overviewScience Direct Topics. Available from: https://www.sciencedirect.com/topics/pharmacology-toxicolog y-and-pharmaceutical-science/epilepsy (Accessed on: 2022 Jun 14).

[6]
Kwan P, Brodie MJ. Emerging drugs for epilepsy. Expert Opin Emerg Drugs  2007; 12(3): 407-22.
 [http://dx.doi.org/10.1517/14728214.12.3.407] [PMID: 17874969]

[7]
Manford M. Recent advances in epilepsy. J Neurol  2017; 264(8): 1811-24.
 [http://dx.doi.org/10.1007/s00415-017-8394-2] [PMID: 28120042]

[8]
Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov  2013; 12(10): 757-76.
 [http://dx.doi.org/10.1038/nrd4126] [PMID: 24052047]

[9]
Aneja S, Sharma S. Newer anti-epileptic drugs. Indian Pediatr  2013; 50(11): 1033-40.
 [http://dx.doi.org/10.1007/s13312-013-0284-9] [PMID: 24382900]

[10]
Thijs RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet  2019; 393(10172): 689-701.
 [http://dx.doi.org/10.1016/S0140-6736(18)32596-0] [PMID: 30686584]

[11]
Tao S, Sun J, Hao F, et al. Effects of sodium valproate combined with lamotrigine on quality of life and serum inflammatory factors in patients with poststroke secondary epilepsy. J Stroke Cerebrovasc Dis  2020; 29(5): 104644.
 [http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2020.104644] [PMID: 32081495]

[12]
Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. Epilepsia  2013; 54(1): 141-55.
 [http://dx.doi.org/10.1111/epi.12028] [PMID: 23167925]

[13]
Stringer JL, Higgins MG. Interaction of phenobarbital and phenytoin in an experimental model of seizures in rats. Epilepsia  1994; 35(1): 216-20.
 [http://dx.doi.org/10.1111/j.1528-1157.1994.tb02936.x] [PMID: 8112250]

[14]
Demchenko IT, Zhilyaev SY, Alekseeva OS, Krivchenko AI, Piantadosi CA, Gasier HG. Increased antiseizure effectiveness with tiagabine combined with sodium channel antagonists in mice exposed to hyperbaric oxygen. Neurotoxicity Research  2019; 36(3)
 [http://dx.doi.org/10.1007/s12640-019-00063-5]

[15]
Doose DR, Brodie MJ, Wilson EA, et al. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia  2003; 44(7): 917-22.
 [http://dx.doi.org/10.1046/j.1528-1157.2003.64402.x] [PMID: 12823574]

[16]
Bernus I, Dickinson RG, Hooper WD, Eadie MJ. The mechanism of the carbamazepine-valproate interaction in humans. Br J Clin Pharmacol  1997; 44(1): 21-7.
 [http://dx.doi.org/10.1046/j.1365-2125.1997.00607.x] [PMID: 9241092]

[17]
Wei CX, Bian M, Gong GH. Current research on antiepileptic compounds. Molecules  2015; 20(11): 20741-76.
 [http://dx.doi.org/10.3390/molecules201119714] [PMID: 26610448]

[18]
Kim K, Lee SG, Kegelman TP, et al. Role of Excitatory Amino Acid Transporter-2 (EAAT2) and glutamate in neurodegeneration: Oppor-tunities for developing novel therapeutics. J Cell Physiol  2011; 226(10): 2484-93.
 [http://dx.doi.org/10.1002/jcp.22609] [PMID: 21792905]

[19]
Sarac S, Afzal S, Broholm H, Madsen FF, Ploug T, Laursen H. Excitatory amino acid transporters EAAT-1 and EAAT-2 in temporal lobe and hippocampus in intractable temporal lobe epilepsy. Acta Pathol Microbiol Scand Suppl  2009; 117(4): 291-301.
 [http://dx.doi.org/10.1111/j.1600-0463.2009.02443.x] [PMID: 19338517]

[20]
Green JL, dos Santos WF, Fontana ACK. Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: Opportunities for novel therapeutics development. Biochem Pharmacol  2021; 193: 114786.
 [http://dx.doi.org/10.1016/j.bcp.2021.114786] [PMID: 34571003]

[21]
Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. The role of Renin–Angiotensin–Aldosterone system and its new components in arterial stiffness and vascular aging. High Blood Press Cardiovasc Prev  2018; 25(2): 137-45.
 [http://dx.doi.org/10.1007/s40292-018-0252-5] [PMID: 29476451]

[22]
Liang JJ, Huang LF, Chen XM, Pan SQ, Lu ZN, Xiao ZM. Amiloride suppresses pilocarpine-induced seizures via ASICs other than NHE in rats. Int J Clin Exp Pathol  2015; 8: 14507.
 [PMID: 4713556]

[23]
DiFrancesco JC, Barbuti A, Milanesi R, et al. Recessive loss-of-function mutation in the pacemaker HCN2 channel causing increased neuronal excitability in a patient with idiopathic generalized epilepsy. J Neurosci  2011; 31(48): 17327-37.
 [http://dx.doi.org/10.1523/JNEUROSCI.3727-11.2011] [PMID: 22131395]

[24]
DiFrancesco JC, DiFrancesco D. Dysfunctional HCN ion channels in neurological diseases. Front Cell Neurosci  2015; 6: 174.
 [http://dx.doi.org/10.3389/fncel.2015.00071] [PMID: 25805968]

[25]
Moloney PB, Cavalleri GL, Delanty N. Epilepsy in the mTORopathies: Opportunities for precision medicine. Brain Commun  2021; 3(4): fcab222.
 [http://dx.doi.org/10.1093/braincomms/fcab222] [PMID: 34632383]

[26]
Curatolo P, Moavero R, van Scheppingen J, Aronica E. mTOR dysregulation and tuberous sclerosis-related epilepsy. Expert Rev Neurother  2018; 18(3): 185-201.
 [http://dx.doi.org/10.1080/14737175.2018.1428562] [PMID: 29338461]

[27]
Vishnoi S, Raisuddin S, Parvez S. Glutamate excitotoxicity and oxidative stress in epilepsy: Modulatory role of melatonin. J Environ Pathol Toxicol Oncol  2016; 35(4): 365-74.
 [http://dx.doi.org/10.1615/JEnvironPatholToxicolOncol.2016016399] [PMID: 27992316]

[28]
Hanada T. Ionotropic glutamate receptors in epilepsy: A review focusing on AMPA and NMDA receptors. Biomolecules  2020; 10(3): 464.
 [http://dx.doi.org/10.3390/biom10030464] [PMID: 32197322]

[29]
Löscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog Neurobiol  1998; 54(6): 721-41.
 [http://dx.doi.org/10.1016/S0301-0082(97)00092-0] [PMID: 9560847]

[30]
Dejakaisaya H, Kwan P, Jones NC. Astrocyte and glutamate involvement in the pathogenesis of epilepsy in Alzheimer’s disease. Epilepsia  2021; 62(7): 1485-93.
 [http://dx.doi.org/10.1111/epi.16918] [PMID: 33971019]

[31]
Fitsanakis VA, Au C, Erikson KM, Aschner M. The effects of manganese on glutamate, dopamine and γ-aminobutyric acid regulation. Neurochem Int  2006; 48(6-7): 426-33.
 [http://dx.doi.org/10.1016/j.neuint.2005.10.012] [PMID: 16513220]

[32]
Marvin JS, Borghuis BG, Tian L, et al. An optimized fluorescent probe for visualizing glutamate neurotransmission. Nature Methods  2013; 10: 162-70.
 [http://dx.doi.org/10.1038/nmeth.2333]

[33]
Rico EP, de Oliveira DL, Rosemberg DB, et al. Expression and functional analysis of Na+-dependent glutamate transporters from zebrafish brain. Brain Res Bull  2010; 81(4-5): 517-23.
 [http://dx.doi.org/10.1016/j.brainresbull.2009.11.011] [PMID: 19941938]

[34]
Abulseoud OA, Camsari UM, Ruby CL, Kasasbeh A, Choi S, Choi DS. Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2. Neuropsychopharmacology  2014; 39(7): 1674-84. https://pubmed.ncbi.nlm.nih.gov/24452391/
 [http://dx.doi.org/10.1038/npp.2014.14] [PMID: 24452391]

[35]
Kalra J, Prakash A, Kumar P, Majeed ABA. Cerebroprotective effects of RAS inhibitors: Beyond their cardio-renal actions. J Renin Angiotensin Aldosterone Syst  2015; 16(3): 459-68. https://pubmed.ncbi.nlm.nih.gov/25944853/
 [http://dx.doi.org/10.1177/1470320315583582] [PMID: 25944853]

[36]
Gouveia TLF, Frangiotti MIB, de Brito JMV, et al. The levels of renin–angiotensin related components are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy. Neurochem Int  2012; 61(1): 54-62.
 [http://dx.doi.org/10.1016/j.neuint.2012.04.012] [PMID: 22542773]

[37]
Albert-Gascó H, Ros-Bernal F, Castillo-Gómez E, Olucha-Bordonau FE. MAP/ERK signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes. International Journal of Molecular Sciences  2020; 21: 4471.
 [http://dx.doi.org/10.3390/ijms21124471]

[38]
Guimond MO, Gallo-Payet N. The angiotensin II Type 2 receptor in brain functions: An update. Int J Hypertens  2012; 2012: 351758.
 [http://dx.doi.org/10.1155/2012/351758] [PMID: 23320146] [PMCID: PMC3540774]

[39]
Krasniqi S, Daci A. Role of the angiotensin pathway and its target therapy in epilepsy management. Int J Mol Sci  2019; 20.
 [http://dx.doi.org/10.3390/ijms20030726] [PMID: 6386974]

[40]
Rusek M, Czuczwar SJ. A review of clinically significant drug-drug interactions involving angiotensin II receptor antagonists and antiepileptic drugs 2020.https://www.tandfonline.com/doi/abs/10.1080/17425255.2020.1763955
 [http://dx.doi.org/10.1080/17425255.2020.1763955]

[41]
Fuster DG, Alexander RT. Traditional and emerging roles for the SLC9 Na+/H+ exchangers. Pflugers Arch  2014; 466(1): 61-76. Available from: https://pubmed.ncbi.nlm.nih.gov/24337822/
 [http://dx.doi.org/10.1007/s00424-013-1408-8] [PMID: 24337822]

[42]
Zhao H, Carney KE, Falgoust L, Pan JW, Sun D, Zhang Z. Emerging roles of Na+/H+ exchangers in epilepsy and developmental brain disorders. Prog Neurobiol  2016; 138-140: 19-35.

[43]
Ali A, Ahmad FJ, Pillai KK, Vohora D. Amiloride protects against pentylenetetrazole-induced kindling in mice. Br J Pharmacol  2005; 145(7): 880-4.
 [http://dx.doi.org/10.1038/sj.bjp.0706291] [PMID: 15951829]

[44]
Attaphitaya S, Park K, Melvin JE. Molecular cloning and functional expression of a rat Na+/H+ exchanger (NHE5) highly expressed in brain. J Biol Chem  1999; 274(7): 4383-8.
 [http://dx.doi.org/10.1074/jbc.274.7.4383] [PMID: 9933642]

[45]
Liang LL, Huang LF, Chen XM, Pan SQ. Amiloride suppresses pilocarpine-induced seizures via ASICs other than NHE in rats. Int J Clin Exp Path  2015; 8(11): 14507-13. Available from: https://www.researchgate.net/publication/317088852_Amiloride_suppresses_pilocarpine-induced_seizures_via_ASICs_other_than_NHE_in_rats

[46]
Balducci V, Credi C, Sacconi L, Romanelli MN, Sartiani L, Cerbai E. The HCN channel as a pharmacological target: Why, where, and how to block it. Prog Biophys Mol Biol  2021; 166: 173-81.
 [http://dx.doi.org/10.1016/j.pbiomolbio.2021.07.010] [PMID: 34303730]

[47]
Kharouf Q, Pinares-Garcia P, Romanelli MN, Reid CA. Testing broad-spectrum and isoform-preferring HCN channel blockers for anti-convulsant properties in mice. Epilepsy Res  2020; 168: 106484.
 [http://dx.doi.org/10.1016/j.eplepsyres.2020.106484] [PMID: 33099130]

[48]
Kessi M, Peng J, Duan H, et al. The Contribution of HCN Channelopathies in Different Epileptic Syndromes, Mechanisms, Modulators, and Potential Treatment Targets: A Systematic Review. Front Mol Neurosci  2022; 15: 807202.
 [http://dx.doi.org/10.3389/fnmol.2022.807202] [PMID: 35663267]

[49]
Concepcion FA, Khan MN, Ju Wang J-D, et al. HCN Channel Phosphorylation Sites Mapped by Mass Spectrometry in Human Epilepsy Patients and in an Animal Model of Temporal Lobe Epilepsy. Neuroscience  2021; 460: 13-30.
 [http://dx.doi.org/10.1016/j.neuroscience.2021.01.038] [PMID: 33571596]

[50]
DiFrancesco JC, Castellotti B, Milanesi R, et al. HCN ion channels and accessory proteins in epilepsy: genetic analysis of a large cohort of patients and review of the literature. Epilepsy Res  2019; 153: 49-58. Available from: https://pubmed.ncbi.nlm.nih.gov/30986657/
 [http://dx.doi.org/10.1016/j.eplepsyres.2019.04.004]

[51]
DiFrancesco JC, Castellotti B, Milanesi R, et al. HCN ion channels and accessory proteins in epilepsy: genetic analysis of a large cohort of patients and review of the literature. Epilepsy Res  2019; 153: 49-58.
 [http://dx.doi.org/10.1016/j.eplepsyres.2019.04.004] [PMID: 30986657]

[52]
Curatolo P, Moavero R. mTOR inhibitors as a new therapeutic option for epilepsy. Expert Rev Neurother  2013; 13(6): 627-38.
 [http://dx.doi.org/10.1586/ern.13.49] [PMID: 23739000]

[53]
Citraro R, Leo A, Constanti A, Russo E, De Sarro G. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res  2016; 107: 333-43.
 [http://dx.doi.org/10.1016/j.phrs.2016.03.039] [PMID: 27049136]

[54]
Zhao XF, Liao Y, Alam MM, et al. Microglial mTOR is Neuronal Protective and Antiepileptogenic in the Pilocarpine Model of Temporal Lobe Epilepsy. J Neurosci  2020; 40(40): 7593-608.
 [http://dx.doi.org/10.1523/JNEUROSCI.2754-19.2020] [PMID: 32868461]

[55]
Nguyen LH, Mahadeo T, Bordey A. mTOR hyperactivity levels influence the severity of epilepsy and associated neuropathology in an experimental model of tuberous sclerosis complex and focal cortical dysplasia. J Neurosci  2019; 39(14): 2762-73.
 [http://dx.doi.org/10.1523/JNEUROSCI.2260-18.2019] [PMID: 30700531]

[56]
Schreiber KH, Arriola Apelo SI, Yu D, et al. A novel rapamycin analog is highly selective for mTORC1 in vivo. Nat Commun  2019; 10(1): 3194.
 [http://dx.doi.org/10.1038/s41467-019-11174-0] [PMID: 31324799]

[57]
Hussein AM, Ghalwash M, Magdy K, Abulseoud OA. Beta lactams antibiotic ceftriaxone modulates seizures, oxidative stress and connexin 43 expression in hippocampus of pentylenetetrazole kindled rats. J Epilepsy Res  2016; 6: 8.

[58]
Jelenkovic AV, Jovanovic MD, Stanimirovic DD, et al. Beneficial effects of ceftriaxone against pentylenetetrazole-evoked convulsions. Exp Biol Med (Maywood)  2008; 233(11): 1389-94.
 [http://dx.doi.org/10.3181/0803-RM-83]

[59]
Chen RC, Huang YH, How SW. Systemic penicillin as an experimental model of epilepsy. Exp Neurol  1986; 92(3): 533-40.
 [http://dx.doi.org/10.1016/0014-4886(86)90295-5] [PMID: 3709733]

[60]
Bo GP, Mainardi P, Benassi E, et al. Parenteral penicillin model of epilepsy in the rat: a reappraisal. Methods Find Exp Clin Pharmacol  1986; 8(8): 491-6.
 [PMID: 3747642]

[61]
Miller RG, Mitchell JD, Moore DH.  2012. Available from: https://pubmed.ncbi.nlm.nih.gov/22419278/

[62]
Sámano C, Nistri A. Mechanism of Neuroprotection Against Experimental Spinal Cord Injury by Riluzole or Methylprednisolone. Neurochem Res  2019; 44(1): 200-13.
 [http://dx.doi.org/10.1007/s11064-017-2459-6] [PMID: 29290040]

[63]
Pacheco-Rojas DO, Delgado-Ramírez M, Villatoro-Gómez K, et al. Riluzole inhibits Kv4.2 channels acting on the closed and closed inactivated states. Eur J Pharmacol  2021; 899: 174026.
 [http://dx.doi.org/10.1016/j.ejphar.2021.174026] [PMID: 33722592]

[64]
Mazzone GL, Nistri A. Delayed neuroprotection by riluzole against excitotoxic damage evoked by kainate on rat organotypic spinal cord cultures. Neuroscience  2011; 190: 318-27.
 [http://dx.doi.org/10.1016/j.neuroscience.2011.06.013] [PMID: 21689734]

[65]
Zgrajka W, Nieoczym D, Czuczwar M, et al. Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. Epilepsy Res  2010; 88(2-3): 269-74.
 [http://dx.doi.org/10.1016/j.eplepsyres.2009.11.010] [PMID: 20015615]

[66]
Borowicz KK, Sekowski A, Drelewska E, Czuczwar SJ. Riluzole enhances the anti-seizure action of conventional antiepileptic drugs against pentetrazole-induced convulsions in mice. Pol J Pharmacol  2004; 56(2): 187-93. https://pubmed.ncbi.nlm.nih.gov/15156069/
 [PMID: 15156069]

[67]
Kim JE, Kim DS, Kwak SE, et al. Anti-glutamatergic effect of riluzole: Comparison with valproic acid. Neuroscience  2007; 147(1): 136-45.
 [http://dx.doi.org/10.1016/j.neuroscience.2007.04.018] [PMID: 17507170]

[68]
Li HH, Lin PJ, Wang WH, et al. Treatment effects of the combination of ceftriaxone and valproic acid on neuronal and behavioural functions in a rat model of epilepsy. Exp Physiol  2021; 106(8): 1814-28.
 [http://dx.doi.org/10.1113/EP089624] [PMID: 34086374]

[69]
Welzel L, Bergin DH, Schidlitzki A, et al. Systematic evaluation of rationally chosen multitargeted drug combinations: a combination of low doses of levetiracetam, atorvastatin and ceftriaxone exerts antiepileptogenic effects in a mouse model of acquired epilepsy. Neurobiol Dis  2021; 149: 105227.
 [http://dx.doi.org/10.1016/j.nbd.2020.105227] [PMID: 33347976]

[70]
Soni N, Koushal P, Reddy BVK, Deshmukh R, Kumar P. Effect of GLT-1 modulator and P2X7 antagonists alone and in combination in the kindling model of epilepsy in rats. Epilepsy Behav  2015; 48: 4-14.
 [http://dx.doi.org/10.1016/j.yebeh.2015.04.056] [PMID: 26037843]

[71]
Rath S, Gupta BK, Bala NN, Dhal HC. Formulation and optimisation of immediate release telmisartan tablets using full factorial design. Int J Appl Pharm  2011; 3(3): 20-4.

[72]
Pushpa VH, Padmaja Shetty K, Suresha RN, Jayanthi MK, Ashwini V, Vaibhavi PS. Evaluation and comparison of anticonvulsant activity of telmisartan and olmesartan in experimentally induced animal models of epilepsy. J Clin Diagn Res  2014; 8(10): HC08-11.

[73]
Łukawski K, Janowska A, Jakubus T, Tochman-Gawda A, Czuczwar SJ. Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock. Eur J Pharmacol  2010; 640(1-3): 172-7.
 [http://dx.doi.org/10.1016/j.ejphar.2010.04.053] [PMID: 20465998]

[74]
Łukawski K, Janowska A, Jakubus T, Czuczwar SJ. Interactions between angiotensin AT 1 receptor antagonists and second-generation antiepileptic drugs in the test of maximal electroshock. Fundam Clin Pharmacol  2014; 28(3): 277-83.
 [http://dx.doi.org/10.1111/fcp.12023] [PMID: 23551463]

[75]
Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia  2001; 42 (Suppl. 3): 8-12.
 [http://dx.doi.org/10.1046/j.1528-1157.2001.042suppl.3008.x] [PMID: 11520315]

[76]
Tchekalarova J, Georgiev V. Angiotensin peptides modulatory system: how is it implicated in the control of seizure susceptibility? Life Sci  2005; 76(9): 955-70.
 [http://dx.doi.org/10.1016/j.lfs.2004.10.012] [PMID: 15607326]

[77]
Giffard RG, Monyer H, Christine CW, Choi DW. Acidosis reduces NMDA receptor activation, glutamate neurotoxicity, and oxygen-glucose deprivation neuronal injury in cortical cultures. Brain Res  1990; 506(2): 339-42.
 [http://dx.doi.org/10.1016/0006-8993(90)91276-M] [PMID: 1967968]

[78]
Ali A, Ahmad FJ, Pillai KK, Vohora D. Evidence of the antiepileptic potential of amiloride with neuropharmacological benefits in rodent models of epilepsy and behavior. Epilepsy Behav  2004; 5(3): 322-8.
 [http://dx.doi.org/10.1016/j.yebeh.2004.01.005] [PMID: 15145301]

[79]
Hanael E, Chai O, Konstanitin L, et al. Telmisartan as an add-on treatment for dogs with refractory idiopathic epilepsy: a nonrandomized, uncontrolled, open-label clinical trial. J Am Vet Med Assoc  2022; 260(7): 735-40.
 [http://dx.doi.org/10.2460/javma.20.12.0683] [PMID: 35201995]

[80]
Ali AA, Pllai KP, Ahmad F, Dua Y. Anticonvulsant effect of amiloride in pentetrazole-induced status epilepticus in mice. Pharmacological Reports  2005; 58(2): 242-5. Available from: https://www.researchgate.net/publication/7078243_Anticonvulsant_effect_of_amiloride_in_pentetrazole-induced_status_epilepticus_in_mice

[81]
Liang J-J, Huang L-F, Chen X-M, Pan S-Q. Amiloride suppresses pilocarpine-induced seizures via ASICs other than NHE in rats. Int J Clinic Experiment Pathol  2015; 8(11): 14507-13.

[82]
Quansah H, N’Gouemo P. Amiloride and SN‐6 suppress audiogenic seizure susceptibility in genetically epilepsy‐prone rats. CNS Neurosci Ther 2014.

[83]
N’Gouemo P. Amiloride delays the onset of pilocarpine-induced seizures in rats. Brain Res  2008; 1222: 230-2.

[84]
Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the Treatment of Cardiovascular Diseases. Circ J  2019; 83(2): 252-60.
 [http://dx.doi.org/10.1253/circj.CJ-18-1184] [PMID: 30606942]

[85]
Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The Clinical Use of Ivabradine. J Am Coll Cardiol  2017; 70(14): 1777-84.
 [http://dx.doi.org/10.1016/j.jacc.2017.08.038] [PMID: 28958335]

[86]
Iacone Y, Morais TP, David F, et al. Systemic administration of ivabradine, a hyperpolarization‐activated cyclic nucleotide‐gated channel inhibitor, blocks spontaneous absence seizures. Epilepsia  2021; 62(7): 1729-43.
 [http://dx.doi.org/10.1111/epi.16926] [PMID: 34018186]

[87]
Sawicka KM, Załuska K, Wawryniuk A, et al. Ivabradine attenuates the anticonvulsant potency of lamotrigine, but not that of lacosamide, pregabalin and topiramate in the tonic-clonic seizure model in mice. Epilepsy Res  2017; 133: 67-70.
 [http://dx.doi.org/10.1016/j.eplepsyres.2017.04.011] [PMID: 28458102]

[88]
Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol  2008; 63(4): 444-53.
 [http://dx.doi.org/10.1002/ana.21331] [PMID: 18389497]

[89]
Sunnen CN, Brewster AL, Lugo JN, et al. Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia  2011; 52(11): 2065-75.
 [http://dx.doi.org/10.1111/j.1528-1167.2011.03280.x] [PMID: 21973019]

[90]
Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci  2009; 29(21): 6964-72.
 [http://dx.doi.org/10.1523/JNEUROSCI.0066-09.2009] [PMID: 19474323]

[91]
Zhang Y, Wang Q, Dong J, et al. [Efficacy of brain-targeted rapamycin for treatment of epilepsy in rats]. Zhejiang Da Xue Xue Bao Yi Xue Ban  2018; 47(5): 457-64. https://pubmed.ncbi.nlm.nih.gov/30693686/
 [PMID: 30693686]

[92]
Marsan E, Baulac S. Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy. Neuropathol Appl Neurobiol  2018; 44(1): 6-17.
 [http://dx.doi.org/10.1111/nan.12463] [PMID: 29359340]

[93]
Curatolo P. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol  2015; 52(3): 281-9.
 [http://dx.doi.org/10.1016/j.pediatrneurol.2014.10.028] [PMID: 25591831]

[94]
Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia  2010; 51(1): 27-36.
 [http://dx.doi.org/10.1111/j.1528-1167.2009.02341.x] [PMID: 19817806]

[95]
French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet  2016; 388(10056): 2153-63.
 [http://dx.doi.org/10.1016/S0140-6736(16)31419-2] [PMID: 27613521]

[96]
 Available from: https://clinicaltrials.gov/ct2/show/results/NCT01713946?term=Rapamycin&cond=Epilepsy&draw=2&rank=7

[97]
Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol  2013; 74(5): 679-87.
 [http://dx.doi.org/10.1002/ana.23960] [PMID: 23798472]

[98]
 Available from: https://clinicaltrials.gov/ct2/show/results/NCT01070316?term=Rapamycin&cond=Epilepsy&draw=2&rank=6

[99]
Cavalcante TMB, De Melo JMA, Lopes LB, et al. Ivabradine possesses anticonvulsant and neuroprotective action in mice. Biomed Pharmacother  2019; 109: 2499-512.
 [http://dx.doi.org/10.1016/j.biopha.2018.11.096] [PMID: 30551511]

[100]
Łuszczki JJ, Prystupa A, Andres-Mach M, Marzęda E, Florek-Łuszczki M. Ivabradine (a hyperpolarization activated cyclic nucleotide-gated channel blocker) elevates the threshold for maximal electroshock-induced tonic seizures in mice. Pharmacol Rep  2013; 65(5): 1407-14.
 [http://dx.doi.org/10.1016/S1734-1140(13)71500-7] [PMID: 24399738]
Rights & Permissions Print Cite
Article Metrics
20
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0115743624252836230924075249	Print ISSN 1574-3624
Publisher Name Bentham Science Publisher	Online ISSN 2212-389X
Current Signal Transduction Therapy

An Update on the Pathways and Aspects of Epilepsy Treatment Targets

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles
